Late-stage failure for Merck and Threshold cancer drug
December 7, 2015Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma
Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
Mylan receives court summons from US Department of Justice
December 7, 2015Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena
The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …
Takeda reveals five-year Adcetris survival data
December 6, 2015Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology
Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
ALG makes senior hires to increase global growth
December 4, 2015Manufacturing and Production, Sales and Marketing
Medical products company ALG has hired Matt Guixe as chief operating officer and Jackie Fisher as chief financial officer. Guixe …
Pfizer to close UK R&D site in surprise move
December 4, 2015Research and Development, Sales and Marketing Pfizer
Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
OBN appoints Dr John Harris as chief executive
December 4, 2015Medical Communications, Sales and Marketing OBN
OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing …
Teva strips $1 billion worth of assets to clear Allergan deal
December 4, 2015Medical Communications, Sales and Marketing Allergan, Teva, acquisitions, divestments, mergers
Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Big Pharma taking steps towards fully digital businesses
December 3, 2015Medical Communications Accenture, digital pharma, innovation
Pharma companies can tap into $100 billion of revenue from being ‘digital transformers’, and not just ‘digital followers’, a leading …
Chief scientific officers appointed at dementia Drug Discovery Alliance
December 3, 2015Medical Communications, Research and Development Alzheimer's Research, dementia, dementia drug discovery alliance
Alzheimer’s Research UK has appointed three chief scientific officers to drive its £30million Drug Discovery Alliance. The Alliance, which unites …
Katja Stout joins Citigate Dewe Rogerson as director
December 3, 2015Medical Communications Citigate Dewe Rogerson
Citigate Dewe Rogerson has appointed of Katja Stout (previously Toon) as a director in its life sciences team. Katja is …
Alkermes aims to take the next biotech step
December 3, 2015Medical Communications, Research and Development Alkermes
“We think we can be the next Biogen, or a Celgene or a Vertex – we have that much firepower …
NICE turns down bone disorder drug for NHS
December 3, 2015Research and Development Alexion, NICE, Strensiq
NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
GSK collaborates on ‘smart inhaler’ technology for respiratory trials
December 3, 2015Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers
GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …
GSK gets European approval for asthma treatment Nucala
December 3, 2015Research and Development GSK, Nucala, asthma
GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …
Janssen in new collaboration to take on TB
December 3, 2015Research and Development FIND, Janssen, antibiotic resistance, tuberculosis
Janssen has announced a new collaboration with the non-profit organisation FIND to step-up the fight against the public health threat …
Second patient dies in Zafgen obesity trial
December 3, 2015Research and Development
Zafgen has announced the death of a second participant in a Phase III clinical trial of its obesity drug beloranib …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
